Rodeo Therapeutics Corporation acquired by Amgen Inc.
Amgen Inc. agreed to acquire Rodeo Therapeutics Corporation, a Seattle, Washington, United States drug development brand, on Mar 30, 2021.
Transaction summary
- Target
- Rodeo Therapeutics Corporation
- Acquirer
- Amgen Inc.
- Seller
- -
- Announced
- 2021-03-30
- Geography
- Seattle, Washington, United States
- Tags
- Biotech
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- 100%
- First added
- 2026-07-25
- Latest update
- 2026-10-29
Value and multiples
100% enterprise value
USD 55.0M
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Amounts paid and other reported values
Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.
Consideration: USD 55.0M
Amgen disclosed $55 million of upfront cash consideration plus contingent milestone payments potentially worth up to an additional $666 million. The price fields reflect only the fixed upfront payment, not the contingent maximum.
Basis
- Maximum potential consideration was $55 million upfront + up to $666 million of contingent milestones = up to $721 million. Only the $55 million fixed upfront consideration is recorded as price.
Source summary
Amgen to Acquire Rodeo Therapeutics Corporation
ConfirmedAmgen announced an agreement to acquire all outstanding Rodeo shares for $55 million upfront in cash and up to $666 million in contingent milestones. Rodeo was described as a Seattle-based biopharmaceutical company developing small-molecule tissue-regeneration and repair therapies.
Open sourceContinue your research
Related transaction comps
ITM Isotope Technologies Munich SE acquired by Telix Pharmaceuticals Limited
2026-09-20 · Confirmed
View transaction → BiotechAtaiBeckley acquired by Eli Lilly and Company
2026-09-11 · Confirmed
View transaction → BiotechDersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction → BiotechEdgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction →